Faculty Appointments
Patient Care Settings
Cancer, Hospital Medicine
Biography
I chose this specialty because of the many exciting new therapeutic options for patients with genitourinary cancers, as well as the opportunity to become an integral part of a team that cares for patients during one of their most difficult times.
As my patient, you can depend on me for compassion and dedication, in addition to an innovative and patient-centered approach to care. My research interests are clinical trials for genitourinary cancers and cancer survivorship research. During my free time, I enjoy running, hiking, cooking and travel.
Conditions I Treat
- Prostate cancer
- Bladder cancer
- Testicular cancer
- Kidney cancer
- Adrenal cancer
Professional Background
Dr. Chunkit Fung graduated Summa Cum Laude with Distinction in Research from Cornell University in 2000. He then went on to Medical School at the University of Pennsylvania in Philadelphia, PA and graduated with his M.D in 2004. He completed his internal medicine Internship and Residency from 2004 through 2007 at the Hospital of the University of Pennsylvania. He held the position of Instructor in the Department of Medicine from the University of Pennsylvania from 2007 to 2008 and subsequently completed his Fellowship in Hematology and Oncology at the Hospital of the University of Pennsylvania from 2008 to 2011. He also received a Master in Clinical Epidemiology in 2012 from the University of Pennsylvania School in Medicine. In July 2011, he came to the University of Rochester School of Medicine and Dentistry as an Assistant Professor in the Department of Hematology and Oncology. His clinical research interests are developing clinical trials to evaluate new therapies in Genitourinary Oncology and Cancer Survivorship Research.
Research
I am a medical oncologist specialized in genitourinary malignancy and an Assistant Professor of medicine with research interests in cancer control, particularly in the development, implementation, and dissemination of mHealth behavioral interventions to prevent and manage treatment- and cancer-related toxicities in cancer survivors, with a specific focus in cardiovascular complications from cancer treatment. Additionally, I am interested in developing clinical trials to evaluate new therapeutics for treatment of urologic malignancies.
Credentials
Specialties
- Medical Oncology - American Board of Internal Medicine
Education
2004
MD | University of Pennsylvania School of Medicine
Post-doctoral Training & Residency
07/01/2008 - 06/01/2011
Fellowship in Hematology & Oncology at UPMC Credentials Verification Office
07/01/2005 - 06/01/2007
Internship in Internal Medicine at UPMC Credentials Verification Office
07/01/2005 - 06/30/2007
Residency in Internal Medicine at UPMC Credentials Verification Office
VIEW ALL expand_more
Awards
2020
Human Rights Campaign Leadership Award for Rising Star Gala Leaders
2019
Presidential Diversity Award Nominee, University of Rochester
2018 - 2018
Civic Leadership Award
Sponsor: US TOO Prostate Cancer Support Group
Location: Rochester, NY
2018
URMC Wilmot Cancer Institute, Hematology/Oncology Fellowship Training Program, Teacher of the Year 2017/2018
2016 - 2018
Empire Clinical Research Investigator Program Fellowship Grant
2016
Strong Star Certificate of Appreciation
2015
Strong Star Certificate of Appreciation
2014
Strong Star Certificate of Appreciation
2013
Strong Star Certificate of Appreciation
2012 - 2015
Wimot Cancer Center Research Fellowship
Sponsor: Wimot Cancer Center
2012
Strong Star Certificate of Appreciation
2012
Patient and Family Centered Care Award
2011
American Society of Clinical Oncology Trainee Travel Award
Sponsor: American Society of Clinical Oncology
2010
National Institute of Health Loan Repayment Program
Sponsor: National Institute of Health
2000
Summa Cum Laude with Distinction in Research
Sponsor: Cornell University
1999
Howard Hughes Medical Institute Undergraduate Research Scholarship
Sponsor: Howard Hughes Medical Institute
VIEW ALL expand_more
Clinical Trials
A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
Lead Researcher: Chunkit Fung
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks (Day 1) plus cabozantinib 40 mg orally daily (Day 1 through Day 21). Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
View Study Details
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Lead Researcher: Chunkit Fung
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
View Study Details
UGUK17036: Monitoring of Treatment Related Toxicities from Oral Targeted Agents and Immunotherapy Among Patients with Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study.
Lead Researcher: Chunkit Fung
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.
View Study Details
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Lead Researcher: Chunkit Fung
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
View Study Details
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Lead Researcher: Chunkit Fung
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
View Study Details
Publications
Journal Articles
9/12/2022
Shahbazi M, Zhang X, Dinh PC, Sanchez VA, Trendowski MR, Shuey MM, Nguyen T, , Feldman DR, Vaughn DJ, Fung C, Kollmannsberger C, Martin NE, Einhorn LH, Cox NJ, Frisina RD, Travis LB, Dolan ME. "Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer." Cancer medicine. 2022 Sep 12; Epub 2022 Sep 12.
6/27/2022
Katragadda C, Fung C, Yousefi-Nooraie R, Cupertino P, Joseph J, Kim Y, Li Y. "Medicare accountable care organizations: post-acute care use and post-surgical outcomes in urologic cancer surgery." Urology.. 2022 Jun 27; Epub 2022 Jun 27.
6/11/2022
Mohile S, Blaum CS, Abadir PM, Dale W, Forman DE, Fung C, Holmes HM, Moslehi J, Mustian KM, Rich MW, Whitson HE. "AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease." Journal of the American Geriatrics Society.. 2022 Jun 11; Epub 2022 Jun 11.
Books & Chapters
2017
Chapter Title: Second Cancers
Book Title: Cancer: Principles & Practice of Oncology, 11th Edition
Author List: Fung, C., Bhatia, S., Allan, J.M., Oeffinger, K.C., Ng, A., Travis L.B.
Edited By: DeVita, V.T. Jr., Lawrence, TS., Rosenberg, S.A.
Published By: Wolters Kluwer Health 2017 in Philadelphia
2014
Chapter Title: Neurotoxicity and Ototoxicity Among Testicular Cancer Survivors
Book Title: EAU-ICUD Consultation on Medical Treatment of Urological Malignancies
Author List: Fung, C., Qi, J, Oldenburg, J
Edited By: Massard C, Zhou FJ, Fossa SD
Published By: EAU-ICUD 2014
2014
Chapter Title: Second Malignant Neoplasms and Cardiovascular Disease Among Testicular Cancer Survivors
Book Title: Testicular Cancer: Diagnosis and Clinical Management
Author List: Fung, C., Fossa SD, Travis LB
Edited By: Einhorn LH, Horwich A, Huddart R
Published By: Oxford: Blackwell Publishing 2014
VIEW ALL PUBLICATIONS